2395 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

2395

TSE Prime

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

1,813

JPY

-44

(-2.37%)

Dec 5, 3:30 pm JST

11.72

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	17,748	4,195	7,078	7,127	171.2	40	May 6, 2022	J-GAAP
Mar, 2023	25,090	5,245	9,194	6,060	145.6	50	May 8, 2023	J-GAAP
Mar, 2024	26,450	4,162	7,015	5,531	132.9	50	May 8, 2024	J-GAAP
Mar, 2025	32,413	2,985	6,450	4,924	118.3	50	May 8, 2025	J-GAAP
Mar, 2026 Guidance	33,272	3,550	5,927	3,550	85.3	50	May 8, 2025	J-GAAP
YoY	+2.7%	+18.9%	-8.1%	-27.9%	-27.9%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 11, 2020	14,808	1,800	2,200	1,800	5	J-GAAP
	Mar 26, 2021	14,808	2,450	3,300	3,300	20	J-GAAP
Results	May 10, 2021	15,110	2,529	3,645	3,661	20	J-GAAP
Mar, 2022	May 10, 2021	Available in future release
	Oct 21, 2021
	Feb 2, 2022
Results	May 6, 2022
Mar, 2023	May 6, 2022
	Jul 29, 2022
	Oct 31, 2022
	Jan 31, 2023
Results	May 8, 2023
Mar, 2024	May 8, 2023
	Aug 2, 2023
	Feb 2, 2024
Results	May 8, 2024
Mar, 2025	May 8, 2024
	Feb 5, 2025
Results	May 8, 2025
Mar, 2026	May 8, 2025	33,272	3,550	5,927	3,550	50	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	4,119	+20.4	Available in future release
Mar, 2002	7,508	+82.3
Mar, 2003	9,550	+27.2
Mar, 2004	12,350	+29.3
Mar, 2005	12,295	-0.4
Mar, 2006	13,805	+12.3
Mar, 2007	17,289	+25.2
Mar, 2008	19,647	+13.6
Mar, 2009	19,540	-0.5
Mar, 2010	19,050	-2.5
Mar, 2011	17,371	-8.8
Mar, 2012	15,273	-12.1
Mar, 2013	17,154	+12.3
Mar, 2014	16,926	-1.3
Mar, 2015	17,835	+5.4
Mar, 2016	14,750	-17.3
Mar, 2017	17,244	+16.9
Mar, 2018	16,600	-3.7
Mar, 2019	15,658	-5.7
Mar, 2020	14,561	-7.0
Mar, 2021	15,110	+3.8
Mar, 2022	17,748	+17.5
Mar, 2023	25,090	+41.4
Mar, 2024	26,450	+5.4
Mar, 2025	32,413	+22.5
Mar, 2026 Guidance	33,272	+2.7	3,550	+18.9	5,927	-8.1	85.3	-27.9

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	26,450	4,162	15.7	18.34	8.28	0.40	132.9
Mar, 2025	32,413	2,985	9.21	13.28	5.84	0.38	118.3
Mar, 2026 Guidance	33,272	3,550	10.7	9.37	3.90	0.37	85.3

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	32,413	5,245	9,194	7,127	171.2
Fiscal Year	Mar, 2025	Mar, 2023	Mar, 2023	Mar, 2022	Mar, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	14,742	2,932	3,266	1,641	39.4	30	May 8, 2023	J-GAAP
Oct - Mar, 2023	14,566	1,813	3,259	2,565	61.6	30	May 8, 2024	J-GAAP
Oct - Mar, 2024	19,905	2,905	4,621	3,593	86.3	30	May 8, 2025	J-GAAP
Oct - Mar, 2025 Guidance	18,506	3,501	4,300	2,489	59.8	30	Nov 7, 2025	J-GAAP
YoY	-7.0%	+20.5%	-6.9%	-30.7%	-30.7%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	5,245	-1,926	4,004	-5,930	6,266	9,197	16.07	J-GAAP
Mar, 2024	4,162	-4,801	2,106	-6,907	5,318	10,274	13.46	J-GAAP
Mar, 2025	2,985	-4,656	7,035	-11,691	5,914	11,843	12.81	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	11,884	2,349	3,756	2,966	71.2	53.5	Nov 7, 2023	J-GAAP
Apr - Sep, 2024	12,508	80	1,829	1,331	32.0	28.4	Nov 6, 2024	J-GAAP
Apr - Sep, 2025	14,766	49	1,627	1,061	25.5	27.5	Nov 7, 2025	J-GAAP
YoY	+18.1%	-38.8%	-11.0%	-20.3%	-20.3%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	6,100	186	1,128	828	19.9	3.0	Feb 2, 2024	J-GAAP
Jan - Mar, 2024	8,466	1,627	2,131	1,737	41.7	19.2	May 8, 2024	J-GAAP
Apr - Jun, 2024	5,549	-145	342	122	2.9	-2.6	Aug 6, 2024	J-GAAP
Jul - Sep, 2024	6,959	225	1,487	1,209	29.0	3.2	Nov 6, 2024	J-GAAP
Oct - Dec, 2024	9,727	1,813	2,309	1,874	45.0	18.6	Feb 5, 2025	J-GAAP
Jan - Mar, 2025	10,178	1,092	2,312	1,719	41.3	10.7	May 8, 2025	J-GAAP
Apr - Jun, 2025	6,477	-340	515	260	6.3	-5.2	Aug 5, 2025	J-GAAP
Jul - Sep, 2025	8,289	389	1,112	801	19.2	4.7	Nov 7, 2025	J-GAAP
YoY	+19.1%	+72.9%	-25.2%	-33.7%	-33.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	3,417	-7.2	Available in future release
Jan - Mar, 2021	4,690	+4.5
Apr - Jun, 2021	3,041	-4.2
Jul - Sep, 2021	4,920	+28.5
Oct - Dec, 2021	4,985	+45.9
Jan - Mar, 2022	4,802	+2.4
Apr - Jun, 2022	4,046	+33.0
Jul - Sep, 2022	6,302	+28.1
Oct - Dec, 2022	6,023	+20.8
Jan - Mar, 2023	8,719	+81.6
Apr - Jun, 2023	5,804	+43.5
Jul - Sep, 2023	6,080	-3.5
Oct - Dec, 2023	6,100	+1.3
Jan - Mar, 2024	8,466	-2.9
Apr - Jun, 2024	5,549	-4.4
Jul - Sep, 2024	6,959	+14.5
Oct - Dec, 2024	9,727	+59.5
Jan - Mar, 2025	10,178	+20.2
Apr - Jun, 2025	6,477	+16.7
Jul - Sep, 2025	8,289	+19.1	389	+72.9	1,112	-25.2	19.2	-33.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	10,178	1,813	3,156	2,475	59.5
Fiscal Year	Mar, 2025	Dec, 2024	Sep, 2022	Sep, 2022	Sep, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	629.60	45.8	57,242	26,211	13,766	0.72	May 8, 2023	J-GAAP
Mar, 2024	819.42	44.7	76,302	34,114	17,215	0.77	May 8, 2024	J-GAAP
Mar, 2025	961.34	43.3	92,416	40,022	20,087	0.86	May 8, 2025	J-GAAP
Apr - Sep, 2025	909.74	41.6	90,978	37,874	19,899	1.01	Nov 7, 2025	J-GAAP

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.(2395) Financial Results